Anticonvulsant medications in the pediatric emergency room and intensive care unit

Pediatric Emergency Care

Volumn 24, Issue 10, 2008, Pages 705-718

  Abend, Nicholas S ^a   Huh, Jimmy W ^b   Helfaer, Mark A ^b   Dlugos, Dennis J ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anticonvulsant medication; Intensive care unit; Seizure; Status epilepticus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CEFAZOLIN; CHLORAMPHENICOL; CISPLATIN; DIAZEPAM; DIGOXIN; ETIRACETAM; FOLINIC ACID; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; METHOTREXATE; MIDAZOLAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RIFAMPICIN; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; ZONISAMIDE;

AGGRESSION; AGRANULOCYTOSIS; ANEMIA; ANTICOAGULATION; ATAXIA; ATRIOVENTRICULAR BLOCK; BEHAVIOR CHANGE; BLOOD DYSCRASIA; BONE DEMINERALIZATION; BRADYCARDIA; BRADYKINESIA; BRAIN DISEASE; BRAIN TUMOR; CEREBELLUM ATROPHY; CHOREOATHETOSIS; CLOSED ANGLE GLAUCOMA; COMA; CONGENITAL HEART DISEASE; DEMENTIA; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRESS SYNDROME; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERACTION; DRUG MECHANISM; DRUG SAFETY; ELECTROENCEPHALOGRAPHY; EMERGENCY WARD; ENZYME INDUCTION; EPILEPTIC STATE; EXFOLIATIVE DERMATITIS; EXTRAVASATION; FEVER; FOCAL EPILEPSY; GINGIVA HYPERPLASIA; GLASGOW COMA SCALE; GRAND MAL EPILEPSY; GRAND MAL SEIZURE; HEART ARREST; HEART ARRHYTHMIA; HEPATITIS; HIRSUTISM; HUMAN; HYPERAMMONEMIA; HYPERPHOSPHATEMIA; HYPOTENSION; INCIDENCE; INJECTION SITE BURNING; INJECTION SITE DISCOLORATION; INJECTION SITE EDEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PARESTHESIA; INTENSIVE CARE UNIT; KETOGENIC DIET; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LETHARGY; LEUKEMIA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LYMPHADENOPATHY; MACULOPAPULAR RASH; MEDICATION ERROR; MONOTHERAPY; NEPHROLITHIASIS; NEUROPROTECTION; NYSTAGMUS; ORGAN TRANSPLANTATION; PANCREATITIS; PANCYTOPENIA; PATHOPHYSIOLOGY; PEDIATRICS; PHLEBITIS; POLYMYOSITIS; PSEUDOLYMPHOMA; PSYCHOSIS; RASH; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SEDATION; SEIZURE; SERUM SICKNESS; SIDE EFFECT; SOFT TISSUE INJURY; STEVENS JOHNSON SYNDROME; SUBARACHNOID HEMORRHAGE; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TRAUMATIC BRAIN INJURY; ADULT; BRAIN HEMORRHAGE; BRAIN INJURY; CHILD; CLASSIFICATION; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; DISEASE MANAGEMENT; EARLY DIAGNOSIS; EMERGENCY; EMERGENCY HEALTH SERVICE; KIDNEY DISEASE; LIVER DISEASE; NEOPLASM; POSTOPERATIVE COMPLICATION; TRANSPLANTATION;

ADULT; ANTICONVULSANTS; BRAIN HEMORRHAGE, TRAUMATIC; BRAIN INJURIES; CHILD; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAPHY; EMERGENCIES; EMERGENCY SERVICE, HOSPITAL; HEART DEFECTS, CONGENITAL; HUMANS; INTENSIVE CARE UNITS, PEDIATRIC; KIDNEY DISEASES; LIVER DISEASES; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; SEIZURES; STATUS EPILEPTICUS; TRANSPLANTATION;

EID: 64249091061     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e318188fcac     Document Type: Review

References (125)

1. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470-472.
2. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989;30:389-399.
3. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1981;22:489-501.
4. Engel J Jr. Report of the ILAE classification core group. Epilepsia. 2006;47:1558-1568.
5. Pellock JM. Overview: definitions and classifications of seizure emergencies. J Child Neurol. 2007;22:9SY13S.
6. Shinnar S, Berg AT, Moshe SL, et al. How long do new-onset seizures in children last? Ann Neurol. 2001;49:659-664.
7. DeLorenzo RJ, Garnett LK, Towne AR, et al. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. Epilepsia. 1999;40:164-169.
8. Eriksson K, Metsaranta P, Huhtala H, et al. Treatment delay and the risk of prolonged status epilepticus. Neurology. 2005;65:1316-1318.
9. Lewena S, Young S. When benzodiazepines fail: how effective is second line therapy for status epilepticus in children? Emerg Med Australas. 2006;18:45-50.
10. Hayashi K, Osawa M, Aihara M, et al. Efficacy of intravenous midazolam for status epilepticus in childhood. Pediatr Neurol. 2007; 36:366-372.
11. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia. 1999;40:120-122.
12. Wasterlan CG, Chen JW. Definition and Classification of Status Epilepticus, in Status Epilepticus, Wasterlain CG, Treiman DM, eds. Cambridge, MA: MIT Press; 2006:11-16.
13. Brevoord JC, Joosten KF, Arts WF, et al. Status epilepticus: clinical analysis of a treatment protocol based on midazolam and phenytoin. J Child Neurol. 2005;20:476-481.
14. Maytal J, Shinnar S, Moshe SL, et al. Low morbidity and mortality of status epilepticus in children. Pediatrics. 1989;83:323-331.
15. Dunn DW. Status epilepticus in children: etiology, clinical features, and outcome. J Child Neurol. 1988;3:167-173.
16. Eriksson KJ, Koivikko MJ. Status epilepticus in children: aetiology, treatment, and outcome. Dev Med Child Neurol. 1997;39:652-658.
17. Chin RF, Neville BG, Peckham C, et al. Incidence, cause, and shortterm outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet. 2006;368:222-229.
18. Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59: 205-210.
19. Holtkamp M, Othman J, Buchheim K, et al. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry. 2005;76:534-539.
20. Holtkamp M, Othman J, Buchheim K, et al. A "malignant" variant of status epilepticus. Arch Neurol. 2005;62:1428-1431.
21. Van Lierde I, Van Paesschen W, Dupont P, et al. De novo cryptogenic refractory multifocal febrile status epilepticus in the young adult: a review of six cases. Acta Neurol Belg. 2003;103:88-94.
22. Wilder-Smith EP, Lim EC, Teoh HL, et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singapore. 2005;34:417-420.
23. Kramer U, Shorer Z, Ben-Zeev B, et al. Severe refractory status epilepticus owing to presumed encephalitis. J Child Neurol. 2005;20: 184-187.
24. Walker M, Cross H, Smith S, et al. Nonconvulsive status epilepticus: Epilepsy Research Foundation Workshop Reports. Epileptic Disord. 2005;7:253-296.
25. Young GB, Jordan KG, Doig GS. An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: an investigation of variables associated with mortality. Neurology. 1996; 47:83-89.
26. Hosain SA, Solomon GE, Kobylarz EJ. Electroencephalographic patterns in unresponsive pediatric patients. Pediatr Neurol. 2005;32: 162-165.
27. Tay SK, Hirsch LJ, Leary L, et al. Nonconvulsive status epilepticus in children: clinical and EEG characteristics. Epilepsia. 2006;47:1504-1509.
28. Jette N, Claassen J, Emerson RG, et al. Frequency and predictors of nonconvulsive seizures during continuous electroencephalographic monitoring in critically ill children. Arch Neurol. 2006;63:1750-1755.
29. Alehan FK, Morton LD, Pellock JM. Utility of electroencephalography in the pediatric emergency department. J Child Neurol. 2001;16:484-487.
30. Abend NS, Dlugos DJ. Non-convulsive status epilepticus in a pediatric intensive care unit. Pediatr Neurol. 2007;37:165-170.
31. O'Regan ME, Brown JK. Serum neuron specific enolase: a marker for neuronal dysfunction in children with continuous EEG epileptiform activity. Eur J Paediatr Neurol. 1998;2:193-197.
32. Vespa PM, Miller C, McArthur D, et al. Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med. 2007;35:2830-2836.
33. Claassen J, Jette N, Chum F, et al. Electrographic seizures and periodic discharges after intracerebral hemorrhage. Neurology. 2007;69: 1356-1365.
34. Dlugos D, Sirven JI. Prognosis of neonatal seizures: "It's the etiology, Stupid"-or is it? Neurology. 2007;69:1812-1813.
35. McBride MC, Laroia N, Guillet R. Electrographic seizures in neonates correlate with poor neurodevelopmental outcome. Neurology. 2000;55: 506-513.
36. Coen RW, McCutchen CB, Wermer D, et al. Continuous monitoring of the electroencephalogram following perinatal asphyxia. J Pediatr. 1982; 100:628-630.
37. Pisani F, Cerminara C, Fusco C, et al. Neonatal status epilepticus vs recurrent neonatal seizures: clinical findings and outcome. Neurology. 2007;69:2177-2185.
38. Ronen GM, Buckley D, Penney S, et al. Long-term prognosis in children with neonatal seizures: a population-based study. Neurology. 2007;69:1816-1822.
39. Trevathan E, Ellen R. Grass lecture: rapid EEG analysis for intensive care decisions in status epilepticus. Am J Electroneurodiagnostic Clin. 2006;46:4-17.
40. Slooter AJ, Vriens EM, Leijten FS, et al. Seizure detection in adult ICU patients based on changes in EEG synchronization likelihood. Neurocrit Care. 2006;5:186-192.
41. Abend NS, Dlugos D, Herman S. Neonatal seizure detection using multichannel display of envelope trend. Epilepsia. 2007;49:349-352.
42. Kolls BJ, Husain AM. Assessment of hairline EEG as a screening tool for nonconvulsive status epilepticus. Epilepsia. 2007;48:959-965.
43. Hirsch LJ, Pang T, Claassen J, et al. Focal motor seizures induced by alerting stimuli in critically ill patients. Epilepsia. 2008;49:968-973.
44. Friedman DE, Schevon C, Emerson RG, et al. Cyclic electrographic seizures in critically ill patients. Epilepsia. 2007;49:282-287.
45. Hirsch LJ, Brenner RP, Drislane FW, et al. The ACNS subcommittee on research terminology for continuous EEG monitoring: proposed standardized terminology for rhythmic and periodic EEG patterns encountered in critically ill patients. J Clin Neurophysiol. 2005;22: 128-135.
46. Chong DJ, Hirsch LJ. Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol. 2005; 22:79-91.
47. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5:246-256.
48. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5:553-564.
49. Helfaer MA, Ware C. Purple glove syndrome. J Neurosurg Anesthesiol. 1994;6:48-49.
50. Wilensky AJ, Lowden JA. Inadequate serum levels after intramuscular administration of diphenylhydantoin. Neurology. 1973;23:318-324.
51. Wolf GK, McClain CD, Zurakowski D, et al. Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. Pediatr Crit Care Med. 2006;7:434-439; quiz 40.
52. Pryor FM, Gidal B, Ramsay RE, et al. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia. 2001;42: 245-250.
53. Ramsay RE, Wilder BJ, Uthman BM, et al. Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin. Epilepsy Res. 1997;28:181-187.
54. Adams BD, Buckley NH, Kim JY, et al. Fosphenytoin may cause hemodynamically unstable bradydysrhythmias. J Emerg Med. 2006;30: 75-79.
55. Uthman BM, Wilder BJ, Ramsay RE. Intramuscular use of fosphenytoin: an overview. Neurology. 1996;46:S24YS28.
56. McBryde KD, Wilcox J, Kher KK. Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient. Pediatr Nephrol. 2005;20: 1182-1185.
57. Dodson WE. Phenytoin and Related Drugs, in Pediatric Epilepsy, Pellock JM, Bourgeois B, Dodson WE, eds. New York: Demos; 2008: 639-651.
58. Leppik IE, Fisher J, Kriel R, et al. Altered phenytoin clearance with febrile illness. Neurology. 1986;36:1367-1370.
59. Limdi NA, Knowlton RK, Cofield SS, et al. Safety of rapid intravenous loading of valproate. Epilepsia. 2007;48:478-483.
60. Morton LD, O'Hara KA, Coots BP, et al. Safety of rapid intravenous valproate infusion in pediatric patients. Pediatr Neurol. 2007;36:81-83.
61. Yu KT, Mills S, Thompson N, et al. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia. 2003;44:724-726.
62. Uberall MA, Trollmann R, Wunsiedler U, et al. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology. 2000;54:2188-2189.
63. White JR, Santos CS. Intravenous valproate associated with significant hypotension in the treatment of status epilepticus. J Child Neurol. 1999; 14:822-823.
64. Bryant AE 3rd, Dreifuss FE, Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology. 1996;46:465-469.
65. Riviello JJ, Ashwal S, Hirtz D, et al. Practice Parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review). Neurology. 2006;67:1542-1550.
66. Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001;56:1405-1409.
67. De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia. 1998;39: 1216-1225.
68. Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006;47:1128-1135.
69. Ramael S, De Smedt F, Toublanc N, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther. 2006;28:734-744.
70. Sankar R, Shields WD. Levetiracetam, in Pediatric Epilepsy, Pellock JM, Bourgeois B, Dodson WE, eds. New York: Demos; 2008:611-619.
71. Mazarati AM, Baldwin R, Klitgaard H, et al. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res. 2004;58:167-174.
72. Rekling JC. Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation. Neurosci Lett. 2003;335:167-170.
73. Gibbs JE, Walker MC, Cock HR. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia. 2006;47:469-478.
74. Glien M, Brandt C, Potschka H, et al. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia. 2002;43: 350-357.
75. Szaflarski JP, Meckler JM, Szaflarski M, et al. Levetiracetam use in critically ill patients. Neurocrit Care. 2007;7:140-147.
76. Patel NC, Landan IR, Levin J, et al. The use of levetiracetam in refractory status epilepticus. Seizure. 2006;15:137-141.
77. Rupprecht S, Franke K, Fitzek S, et al. Levetiracetam as a treatment option in non-convulsive status epilepticus. Epilepsy Res. 2007;73: 238-244.
78. Rossetti AO, Bromfield EB. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav. 2006;8:651-654.
79. Trabacca A, Profice P, Costanza MC, et al. Levetiracetam in nonconvulsive status epilepticus in childhood: a case report. J Child Neurol. 2007;22:639-641.
80. Oberndorfer S, Piribauer M, Marosi C, et al. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol. 2005;72:255-260.
81. Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet. 2000;356:285-290.
82. Glauser TA. Topiramate, in Pediatric Eplepsy, Pellock JM, Bourgeois B, Dodson WE, eds. New York: Demos; 2008:671-683.
83. Niebauer M, Gruenthal M. Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res. 1999;837:263-269.
84. Yang Y, Shuaib A, Li Q, et al. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res. 1998;804:169-176.
85. Cha BH, Silveira DC, Liu X, et al. Effect of topiramate following recurrent and prolonged seizures during early development. Epilepsy Res. 2002;51:217-232.
86. Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia. 1998;39:1324-1328.
87. Kahriman M, Minecan D, Kutluay E, et al. Efficacy of topiramate in children with refractory status epilepticus. Epilepsia. 2003;44: 1353-1356.
88. Perry MS, Holt PJ, Sladky JT. Topiramate loading for refractory status epilepticus in children. Epilepsia. 2006;47:1070-1071.
89. Blumkin L, Lerman-Sagie T, Houri T, et al. Pediatric refractory partial status epilepticus responsive to topiramate. J Child Neurol. 2005;20: 239-241.
90. Towne AR, Garnett LK, Waterhouse EJ, et al. The use of topiramate in refractory status epilepticus. Neurology. 2003;60:332-334.
91. Bensalem MK, Fakhoury TA, Topiramate and status epilepticus: report of three cases. Epilepsy Behav. 2003;4:757-760.
92. Reuber M, Evans J, Bamford JM. Topiramate in drug-resistant complex partial status epilepticus. Eur J Neurol. 2002;9:111-112.
93. The Management of a Child (aged 0-18 years) with a Decreased Conscious Level. The Paediatric Accident and Emergency Research Group. 2006; http://www.nottingham.ac.uk/paediatric-guideline/. Accessed Jan 9, 2008.
94. Sarnaik AP, Meert K, Hackbarth R, et al. Management of hyponatremic seizures in children with hypertonic saline: a safe and effective strategy. Crit Care Med. 1991;19:758-762.
95. Chamberlain JM, Altieri MA, Futterman C, et al. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care. 1997;13:92-94.
96. Shah I, Deshmukh CT. Intramuscular midazolam vs intravenous diazepam for acute seizures. Indian J Pediatr. 2005;72:667-670.
97. Mpimbaza A, Ndeezi G, Staedke S, et al. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics. 2008;121: c58Yc64.
98. Baysun S, Aydin OF, Atmaca E, et al. A comparison of buccal midazolam and rectal diazepam for the acute treatment of seizures. Clin Pediatr (Phila). 2005;44:771-776.
99. McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366:205-210.
100. Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353:623-626.
101. Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004;5:253-255.
102. Fisgin T, Gurer Y, Tezic T, et al. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. J Child Neurol. 2002;17:123-126.
103. Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol. 2006;34: 355-359.
104. Dreifuss FE, Rosman NP, Cloyd JC, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med. 1998;338:1869-1875.
105. Cereghino JJ, Mitchell WG, Murphy J, et al. Treating repetitive seizures with a rectal diazepam formulation: a randomized study. The North American Diastat Study Group. Neurology. 1998;51:1274-1282.
106. O'Dell C, Shinnar S, Ballaban-Gil KR, et al. Rectal diazepam gel in the home management of seizures in children. Pediatr Neurol. 2005;33: 166-172.
107. Kriel RL, Cloyd JC, Pellock JM, et al. Rectal diazepam gel for treatment of acute repetitive seizures. The North American Diastat Study Group. Pediatr Neurol. 1999;20:282-288.
108. Glauser TA. Designing practical evidence-based treatment plans for children with prolonged seizures and status epilepticus. J Child Neurol. 2007;22:38SY46S.
109. Ryvlin P. Optimizing therapy of seizres in specific clinical situations. Neurology. 2006;67.
110. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54:1886-1893.
111. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2:473-481.
112. Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology. 2006;67:S10YS13.
113. Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology. 2006; 67:S28YS33.
114. Chabolla DR, Wszolek ZK. Pharmacologic management of seizures in organ transplant. Neurology. 2006;67:S34YS38.
115. Clancy RR, Sharif U, Ichord R, et al. Electrographic neonatal seizures after infant heart surgery. Epilepsia. 2005;46:84-90.
116. Saengpattrachai M, Sharma R, Hunjan A, et al. Nonconvulsive seizures in the pediatric intensive care unit: etiology, EEG, and brain imaging findings. Epilepsia. 2006;47:1510-1518.
117. Levine M, Sheppard I. Biphasic interaction of phenytoin with warfarin. Clin Pharm. 1984;3:200-203.
118. Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis. J Neurotrauma. 2007;24(suppl 1):S83YS86.
119. Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, doubleblind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990;323:497-502.
120. Liu KC, Bhardwaj A. Use of prophylactic anticonvulsants in neurologic critical care: a critical appraisal. Neurocrit Care. 2007;7:175-184.
121. Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg. 1999;91:593-600.
122. Young KD, Okada PJ, Sokolove PE, et al. A randomized, doubleblinded, placebo-controlled trial of phenytoin for the prevention of early posttraumatic seizures in children with moderate to severe blunt head injury. Ann Emerg Med. 2004;43:435-446.
123. Lewis RJ, Yee L, Inkelis SH, et al. Clinical predictors of post-traumatic seizures in children with head trauma. Ann Emerg Med. 1993;22: 1114-1118.
124. Adelson PD, Bratton SL, Carney NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 19. The role of anti-seizure prophylaxis following severe pediatric traumatic brain injury. Pediatr Crit Care Med. 2003;4:S72YS75.
125. Chumnanvej S, Dunn IF, Kim DH. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery. 2007;60: 99-102; discussion 3.